SYNTERMED, INC.

Syntermed, Inc. is a medical software company specializing in advanced diagnostic imaging analysis tools for nuclear cardiology, brain imaging, and PSMA PET/CT scanning. The company develops FDA-cleared, ISO 13485-certified software solutions that enhance clinical value and diagnostic accuracy across multiple imaging modalities. Primary product lines include the Cardiac Toolbox (eCTB), a comprehensive multi-modality platform for SPECT, PET, calcium scoring, myocardial blood flow, and strain analysis with integrated reporting and remote reading capabilities; NeuroQ 4, brain imaging analysis software for FDG-PET, Amyloid, SPECT, and DatScan imaging; and aPROMISE, a deep learning application for quantitative PSMA PET/CT assessment. Syntermed Live enables remote, cloud-based reading and reporting for nuclear cardiology studies. The company's Smart Scores technology provides automated quantitative segmental analysis with natural language report generation and physician decision support. Products are designed for nuclear medicine departments, cardiology practices, and neuroimaging centers. Syntermed has been the exclusive licensee of the Emory Cardiac Toolbox for over 25 years and recently acquired the intellectual property rights. The company maintains FDA Quality System Records and Pre-Market Notification (510(k)) clearance, along with European Union CE Mark (ISO 13485:2016) certification. All medical devices comply with applicable regulatory frameworks for diagnostic imaging software in the United States and European markets.